Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...

Amgen's experimental drug MariTide helped overweight or obese patients lose up to 20% weight on average in a year-long ...

MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...

An Amgen obesity drug helped participants lose a substantial amount of weight, but questions about how competitive it could ...

Recent data from an Amgen obesity-drug trial only reinforced investors' impressions that Eli Lilly and Novo Nordisk have a prohibitive head start, thanks, in particular, to a new generation of Lilly ...

The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...